Sign in
Taking people in ChilePhase 2/3

Tests izalontamab brengitecan against standard chemotherapy in untreated triple-negative breast cancer

Compares a new antibody-drug combination with chemotherapy in adults with advanced triple-negative breast cancer.

Key facts

Who runs it
Bristol-Myers Squibb
Where
Santiago and Viña del Mar, ChileSee the 5 sitesAlso in 27 other countries, 284 sites
Trial code
Registry title
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Status
Recruiting
Phase
Phase 2/3
People taking part
600 people, planned
Started
11 Sept 2025
Expected to end
15 May 2030
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Iza-bren
  • Nab-paclitaxel
  • Paclitaxel
  • Capecitabine
  • Carboplatin
  • Gemcitabine
Record updated
10 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with triple-negative or ER-low, HER2-negative breast cancer that is advanced, cannot be removed by surgery, or has spread. They must not have had treatment yet for this stage and cannot have anti-PD(L)1 drugs.

Age
18 years or older
Sex
Men and women can join
Disease stage
Locally advanced, recurrent inoperable, or metastatic triple-negative breast cancer, or ER-low, HER2-negative breast cancer. The disease must be measurable on CT or MRI.
Earlier treatment
No earlier systemic therapy for the advanced or metastatic disease. If the cancer came back, it must be at least 6 months after the last treatment meant to remove all of the disease. Anti-PD(L)1 drugs must not be an option. ER-low patients must not be able to have hormone-based treatment.
Biomarker or test result
Triple-negative: ER < 1%, PgR < 1%, HER2 IHC 0, 1+, or 2+ with no HER2 gene amplification. ER-low: ER and/or PgR 1% to 10%, HER2-negative.

Main reasons for not taking part

  • Known germline BRCA1 or BRCA2 mutation when a PARP inhibitor is the preferred first treatment
  • Untreated brain or spinal cord metastases causing symptoms
  • Metastases in the membranes around the brain and spinal cord (leptomeningeal)
  • Serious heart disease, including heart failure, recent heart attack or stroke, or LVEF < 50%
  • Earlier treatment with iza-bren or a similar drug targeting EGFR or HER3 or with a topoisomerase 1 inhibitor

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Histologically or cytologically confirmed and documented locally-advanced, recurrent inoperable, or metastatic triple-negative breast cancer (TNBC) (ER < 1%, PgR < 1%, HER2 IHC 0, 1+, or 2+ with ISH negative for HER2 gene amplification) or ER-low, HER2-negative BC (ER and / or PgR 1% to 10%, HER2 IHC 0, 1+, or 2+ with ISH negative for HER2 gene amplification) per American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) criteria, based on the most recently analyzed biopsy or other pathology specimen
  • Patients with recurrent disease must have experienced disease relapse at least 6 months after finishing their last therapy with curative intent
  • Participants with TNBC must be considered ineligible for 1L chemotherapy combination treatment with an anti-PD-1 (eg, pembrolizumab) or an anti-PD-L1 (eg, atezolizumab) due to any one of the following criteria:; Investigator-determined ineligibility based on PD-L1 negative disease determined and documented prior to trial screening as part of standard of care (SoC); ii) Has experienced disease relapse between 6 to 12 months after the completion of (neo)adjuvant therapy with an anti-PD(L)1; iii) Has a severe auto-immune disease or other contraindication, in the opinion of the investigator, for the use of an anti-PD(L)1 drug: iv) Any auto-immune disease that requires current immunosuppression (eg, methotrexate, cyclophosphamide, prednisone > 10 mg/day); Prior auto-immune AE to peri-adjuvant ICI that required immunosuppression. vi) Current Graves' disease with ophthalmopathy or in need of radioiodine or in use of antithyroid medication
  • Current or prior auto-immune diseases per below: A. Moderate to severe rheumatoid arthritis. B. Auto-immune hepatitis or cholangitis. C. Myasthenia gravis. D. Moderate-to-severe or poorly controlled inflammatory bowel disease. E. Multiple sclerosis. F. Lupus with kidney involvement or moderate to severe lupus. G. Auto-immune myocarditis. Note: if participant meets Inclusion Criteria 5b or 5c, unknown PDL1 results per local SOC are acceptable in these specific cases
  • Patients with ER-low, HER2-negative BC must be ineligible, in the opinion of the Investigator, for endocrine therapy-based treatments
  • No previous systemic therapy in the locally advanced, recurrent inoperable or metastatic setting (ie incurable setting)
  • Measurable disease by CT or MRI as per RECIST v1.1

Who cannot take part

  • Untreated symptomatic central nervous system (CNS) metastases. Participants are eligible if CNS metastases have been treated, and participants' neurological signs and symptoms have returned to baseline. In addition, participants must have been either off corticosteroids, or on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to randomization. Imaging performed within 28 days of randomization must document radiographic stability of CNS lesions and be performed after completion of any CNS directed therapy
  • Participants with a known germline breast cancer gene (BRCA) 1 or 2 mutation whose best 1L treatment option, in the opinion of the investigator, is a poli-ADP-ribose-polymerase inhibitors (PARPi)
  • Participants with history of severe heart disease including, but not limited to, any of the following:; History of clinically significant heart disease (eg, cardiomyopathy, congestive heart failure with New York Heart Association functional classification II to IV, pericarditis, or significant pericardial effusion)
  • Myocardial infarction, uncontrolled angina, or stroke/transient ischemic attack within the past 6 months
  • QTc (by Fridericia's formula) prolongation ≥ 450 msec for males and ≥ 470 msec for females, except for right bundle branch block
  • Known LVEF < 50%
  • Prior therapy with iza-bren or any other ADC targeting EGFR and/or HER3 or containing a topoisomerase 1 inhibitor payload
  • Leptomeningeal metastases
  • Other protocol-defined Inclusion/Exclusion criteria apply

This trial is currently available in Chile.

Also in 27 other countries, 284 sites

  • BradfordhillSantiago, ChileContact: Carlos Gallardo, Site 0018Taking people
  • Clinica Alemana de SantiagoSantiago, ChileContact: Jose Sola, Site 0021Taking people
  • FALPSantiago, ChileContact: Felipe Reyes, Site 0138Taking people
  • Pontificia Universidad Catolica de ChileSantiago, ChileContact: Cesar Sanchez, Site 0017Taking people
  • Oncocentro ApysViña del Mar, ChileContact: Alejandro Acevedo Gaete, Site 0016Taking people

About the trial

What the trial wants to find out

The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates for anti-PD(L)1 therapy and endocrine therapies.

The 3 groups in the trial

  • Arm A1Treatment being tested

    Treatment: Iza-bren

  • Arm A2Treatment being tested

    Treatment: Iza-bren

  • Arm BExisting treatment, for comparison

    Treatment: Nab-paclitaxel, Paclitaxel, Capecitabine, Carboplatin, and Gemcitabine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
IZABRIGHT-Breast01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment
Plain-language title
Tests izalontamab brengitecan against standard chemotherapy in untreated triple-negative breast cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
10 August 2026